SelectScience
Join Free
Accelerating Science
NewsLife Sciences

Crown Bioscience to Commercialize University of York's Prostate Cancer Models for Drug Development

Crown Bioscience

Crown Bioscience to Commercialize University of York's Prostate Cancer Models for Drug Development

15 Feb 2016
Alex Waite
Editorial Assistant

Industry news

Crown Bioscience Inc., a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has reached an agreement with UK’s University of York to exclusively license and commercialize the university’s unique collection of patient-derived xenograft (PDX) models for prostate cancer.

Prostate cancer is the second most common cancer in men, impacting more than 14 million patients worldwide. The disease has long been underrepresented at the preclinical modeling stage of drug development, and as such, Crown Bioscience is anticipating significant demand for this new service offering.

“This agreement benefits cancer researchers around the world because these models will now become more widely available,” Jean-Pierre Wery, PhD., president of Crown Bioscience. “With this agreement, we can offer researchers one of the largest, if not the largest, collection of well-validated prostate cancer PDX models. The university’s models will be marketed alongside our industry-leading HuPrime® collection and run to CrownBio’s meticulous standard.”

CrownBio intends to expand characterization, including next generation sequencing, of the models, and ultimately to develop new models resistant to current clinical therapies. Derived from primary tissue, the collection includes pretreated and naïve material, plus examples of both clinically diagnosed castration-resistant (CRPC) and hormone sensitive prostate cancer.

The models were developed by Dr. Anne Collins in the laboratory of Professor Norman Maitland in the Department of Biology at the University of York, with major funding from the independent regional charity Yorkshire Cancer Research. “Since setting up the YCR Cancer Research Unit at the University of York in 1980, our researchers have advanced our understanding of the genetic makeup of prostate cancer and how it can be detected and treated. These models can now become a resource for researchers all over the world,” said Charles Rowett, CEO at Yorkshire Cancer Research.

“We’re delighted to work with CrownBio, the market leader in PDX and translational models, to help us bring these models to the wider research community,” said Maitland, director of the YCR Cancer Research Unit at York. “For many years, the preclinical development of the new therapies, sorely needed for prostate cancer, has relied on testing in models derived in the 1980s. Researchers will now be able to use multiple near-patient xenografts, from different stages and grades of prostate cancer. This initiative should provide the best indicator yet to drug developers of the particular patient group in which a new treatment will be most effective.”

For more information about the entire line of Crown Bioscience translational platforms, visit www.crownbio.com.

About Yorkshire Cancer Research

Yorkshire Cancer Research (Registered Charity 516898) is the largest independent regional cancer charity in England. The charity aims to invest £100m over the next 10 years in order to save 2,000 lives in Yorkshire every year by 2025. For more information, please visit www.ycr.org.uk.

Links

Crown BioscienceCompany website

Tags

Sample PreparationSample preparation can improve the quality and speed of separation techniques. Products to assist sample preparation include filtration equipment, evaporators, membranes and sieves.Data AnalysisData analysis hardware and software is available to make data processing straight-forward yet powerful. Data software can be used for math and stats, technical graphing and image analysis. In addition, software is available for specific data analysis of electrophoresis, densitometry, ELISA and DNA sequencing.Sample ManagementSample management systems include sample storage devices such as freezers and plate storers, sample environment enclosures and sample organization, retrieval and sorter systems. Useful system features include high-throughput, automation, robotic arms, automated liquid handling and associated database systems. Accessories in sample management include barcode scanners, heat sealers and tubes.Cellular PathologyCellular Pathology deals with the microscopic analysis of tissue samples and cells. Sample preparation and processing includes fixation, staining, sectioning and slide mounting, using equipment such microtomes and cryostats. In choosing immunohistochemistry and immunocytochemistry kits, consider chromogens, staining method, antibodies, microscopes and imaging.Biopharmaceutical AdvancesBiopharmaceutical advances follow the development of pharmaceuticals derived from biotechnology, also known as biotechnology medicines. Biopharmaceuticals may be produced from cell lines, plants, or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification.Clinical GeneticsMolecular Genetics covers the analysis of hereditary genetic disease and chromosomal abnormalities. Genetics can be analysed using DNA, RNA, and protein microarrays, PCR, RT PCR and DNA sequencing. Genetic equipment includes genetic workstations, thermal cyclers, cooling blocks and electrophoresis products. Diagnostic kits are used for DNA / RNA extraction and purification.Next Generation SequencingNext-generation sequencing (NGS), also known as whole-genome sequencing, high-throughput sequencing and massive parallel sequencing, produces and analyses thousands to millions of nucleotide sequences at once. Sequencing systems operate via varying technologies depending on the manufacturer, including sequencing by synthesis, ligation, pyrosequencing, ion semiconductor and single-molecule real-time sequencing. For NGS, library preparation is paramount to successful sequencing. In this section, explore a range of library preparation kits, from targeted, amplicon-based or hybridization-based kits including epigenomic, transcriptomic and genomic workflows to fragmentation kits. Find the best next-generation sequencing products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Drug DeliveryDrug Delivery refers to dosage form, route of administration, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect. Drug delivery is often approached via the biopharmaceutical or small molecule drug's formulation, but it may also involve medical devices or drug-device combination products. Considerations include instrumentation, software and services. RegulatoryPharmaceutical regulations impact on all areas of drug development, manufacture and control and supply. Services are provided from the early stages of drug development and clinical trials through to dossier submission, approval and marketing. Regulatory also includes submission of analytical studies from the pharmaceutical product and safety. Prostate CancerCancer DiagnosticsThere are a wide variety of diagnostic tests for cancer available, and this range continues to expand as our knowledge of cancer improves. Current diagnostic methods include biopsy, imaging and blood tests for known biomarkers. New methods in research development include liquid biopsies and cancer breathalyzers.Drug DevelopmentDrug development refers to the process of bringing a new drug to market.Cancer ResearchAlthough cancer is often referred to as a single condition, it actually consists of more than 100 different diseases. Microscopy, mass spectrometry, high throughput sequencing and flow cytometry are some of the most common techniques employed in cancer research labs.

Related articles

Crown Bioscience to Commercialize University of York's Prostate Cancer Models for Drug Development